12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Sigilon Therapeutics (NASDAQ:SGTX) stock rose 15.5% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $48.1 million.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Tenax Thearpeutics Reports Was Granted US Patent For Subcutaneous Use Of Levosimendan
Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition
Patent Term to 2039, Exclusive of Any Possible Extensions
MORRISVILLE, N.C., Jan. 12, 2022
Tenax Therapeutics Shares Move Over $1 Level Following Circulation Of Zack’s Small Cap Research Note Highlighting $4.50 Valuation Target On Stock
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_01052021_TENX_Vandermosten.pdf
Tenax Therapeutics Receives Notice Of Allowance Of Multiple Patent Claims For TNX-102
Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need,
TENX: Second Quarter Results
By John Vandermosten, CFA
NASDAQ:TENX
READ THE FULL TENX RESEARCH REPORT
Tenax Therapeutics Q2 EPS $(0.10) Beats $(0.13) Estimate
Tenax Therapeutics (NASDAQ:TENX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 56.52 percent increase over losses of $(0.23) per share
Tenax Announces Publication Highlighting Novel Levosimendan Mechanism Of Action In Pulmonary Hypertension Patients With Heart Failure And Preserved Ejection Fraction
Levosimendan was shown to Reduce Stressed Blood Volume (SBV), a Novel and Highly Relevant Mechanism of Action for PH-HFpEF Patients
Stressed Blood Volume Reductions Accompany Previously Reported Improvements in
45 Biggest Movers From Yesterday
Gainers
Entera Bio Ltd. (NASDAQ: ENTX) shares surged 44.8% to close at $6.50 on Wednesday after the company reported topline Phase 2 bone mineral density data for EB613.